1887

Abstract

is the second most common cause of non-tuberculosis mycobacterial diseases in Sao Paulo, Brazil. An important component of the management of infections caused by this organism is antibiotic susceptibility testing. The objective of this study was to determine the drug susceptibility profiles and genotypes of clinical isolates of obtained from patients with or without an infection that met the American Thoracic Society's case definition criteria of disease. One hundred and sixty-nine clinical isolates of collected between 1993 and 1998 in Sao Paulo, Brazil, were tested consecutively. The isolates were genotyped by PCR restriction-enzyme pattern analysis (PRA). Most of the strains were susceptible to isoniazid, streptomycin, rifabutin, rifampicin, clarithromycin, ethionamide, amikacin, clofazimine and cycloserine, and resistant to ethambutol, ciprofloxacin and doxycycline. Of 169 isolates, 167 belonged to the type I PRA genotype and one each belonged to type II and III genotypes. There was no correlation between PRA subtype and disease according to the American Thoracic Society case definition. Clinical trials may be needed to better correlate MIC values with treatment outcomes to identify appropriate parameters for drug-resistance testing of .

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.45965-0
2005-10-01
2019-11-17
Loading full text...

Full text loading...

/deliver/fulltext/jmm/54/10/JM541012.html?itemId=/content/journal/jmm/10.1099/jmm.0.45965-0&mimeType=html&fmt=ahah

References

  1. Ahn, C. H., McLarty, J. W., Ahn, S. S., Ahn, I. & Hurst, G. A. ( 1982;). Diagnostic criteria for pulmonary disease caused by Mycobacterium kansasii and Mycobacterium intracellulare. Am Rev Respir Dis 125, 388–391.
    [Google Scholar]
  2. Alcaide, F., Richter, I., Bernasconi, C. & 7 other authors ( 1997;). Heterogeneity and clonality among isolates of Mycobacterium kansasii: implications for epidemiological and pathogenicity studies. J Clin Microbiol 35, 1959–1964.
    [Google Scholar]
  3. Alcaide, F., Benitez, M. A. & Martin, R. ( 1999;). Epidemiology of Mycobacterium kansasii. Ann Intern Med 131, 310–311.
    [Google Scholar]
  4. American Thoracic Society ( 1990;). Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am Rev Respir Dis 142, 940–953.[CrossRef]
    [Google Scholar]
  5. American Thoracic Society ( 1997;). Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Resp Crit Care Med 156, S1–S25.[CrossRef]
    [Google Scholar]
  6. Bamberger, D. M., Driks, M. R., Gupta, M. R., O'Connor, M. C., Jost, P. M., Neihart, R. E., McKinsey, D. S., Moore, L. A. & the Kansas City AIDS Research Consortium ( 1994;). Mycobacterium kansasii among patients infected with the human immunodeficiency virus in Kansas City. Clin Infect Dis 18, 395–400.[CrossRef]
    [Google Scholar]
  7. Bittner, M. J., Horowitz, E. A., Safranek, T. J. & Preheim, L. C. ( 1996;). Emergence of Mycobacterium kansasii as the leading mycobacterial pathogen isolated over a 20-year period at a midwestern Veterans Affairs hospital. Clin Infect Dis 22, 1109–1110.[CrossRef]
    [Google Scholar]
  8. Bloch, K. C., Zwerling, L., Pletcher, M. J., Hahn, J. A., Gerberding, J. L., Ostroff, S. M., Vugia, D. J. & Reingold, A. L. ( 1998;). Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study. Ann Intern Med 129, 698–704.[CrossRef]
    [Google Scholar]
  9. Bolivar, R., Satterwhite, K. T. & Floyd, M. ( 1980;). Cutaneous lesions due to Mycobacterium kansasii. Arch Dermatol 116, 207–208.[CrossRef]
    [Google Scholar]
  10. Chobot, S., Malis, J., Sebakova, H., Pelikan, M., Zatloukal, O., Palicka, P. & Kocurova, D. ( 1997;). Endemic incidence of infections caused by Mycobacterium kansasii in the Karvina district in 1968–1995 (analysis of epidemiological data – review). Cent Eur J Public Health 5, 164–173.
    [Google Scholar]
  11. Evans, S. A., Colville, A., Evans, A. J., Crisp, A. J. & Johnston, I. D. A. ( 1996;). Pulmonary Mycobacterium kansasii infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis. Thorax 51, 1248–1252.[CrossRef]
    [Google Scholar]
  12. Ferrazoli, L., Silva, E. A. M., Martins, M. C., Ichikawa, T. & Palaci, M. ( 1992;). Mycobacteria other than M.tuberculosis. Important aspects concerning frequency and diagnosis of infection. Hansen Int 17, 15–20 (in Portuguese).
    [Google Scholar]
  13. Inderlied, C. B. & Pfyffer, G. E. ( 2003;). Susceptibility test methods: Mycobacteria. In Manual of Clinical Microbiology, 8th edn, pp. 1149–1177. Washington, DC: American Society for Microbiology.
  14. Nachamkin, I., MacGregor, R. R., Staneck, J. L., Tsang, A. Y., Denner, J. C., Willner, M. & Barbagallo, S. ( 1992;). Niacin-positive Mycobacterium kansasii isolated from immunocompromised patients. J Clin Microbiol 30, 1344–1346.
    [Google Scholar]
  15. Picardeau, M., Prodhom, G., Raskine, L., Lepennec, M. P. & Vincent, V. ( 1997;). Genotypic characterization of five subspecies of Mycobacterium kansasii. J Clin Microbiol 35, 25–32.
    [Google Scholar]
  16. Rooney, G., Nelson, M. R. & Gazzard, B. ( 1996;). Mycobacterium kansasii: its presentation, treatment and outcome in HIV infected patients. J Clin Pathol 49, 821–823.[CrossRef]
    [Google Scholar]
  17. Ross, B. C., Jackson, K., Yang, M., Sievers, A. & Dwyer, B. ( 1992;). Identification of a genetically distinct subspecies of Mycobacterium kansasii. J Clin Microbiol 30, 2930–2933.
    [Google Scholar]
  18. Sato, D. N., Silva, E. A. M., Ferrazoli, L. & Palaci, M. ( 1993;). ‘In vitro’ activity of different drugs against Mycobacterium kansasii. Rev Inst Adolfo Lutz 53, 55–58 (in Portuguese).
    [Google Scholar]
  19. Schraufnagel, D. E., Leech, J. A. & Pollak, B. ( 1986;). Mycobacterium kansasii: colonization and disease. Br J Dis Chest 80, 131–137.[CrossRef]
    [Google Scholar]
  20. Shafer, R. W. & Sierra, M. F. ( 1992;). Mycobacterium xenopi, Mycobacterium fortuitum, Mycobacterium kansasii, and other nontuberculous mycobacteria in an area of endemicity for AIDS. Clin Infect Dis 15, 161–162.[CrossRef]
    [Google Scholar]
  21. Sherer, R., Sable, R., Sonnenberg, M., Cooper, S., Spencer, P., Schwimmer, S., Kocka, F., Muthuswamy, P. & Kallick, C. ( 1986;). Disseminated infection with Mycobacterium kansasii in the acquired immunodeficiency syndrome. Ann Intern Med 105, 710–711.[CrossRef]
    [Google Scholar]
  22. Silva, E. A. M., Miranda, J. B. N., Ferrazoli, L., Alge, M. E., Silva, R. R. F., Fuzihara, T. O. & Palaci, M. ( 1987;). Pulmonary infections due to M.kansasii in Sao Paulo, Brazil. Rev Inst Adolfo Lutz 47, 11–17 (in Portuguese).
    [Google Scholar]
  23. Taillard, C., Greub, G., Weber, R. & 11 other authors ( 2003;). Clinical implications of Mycobacterium kansasii species heterogeneity: Swiss national survey. J Clin Microbiol 41, 1240–1244.[CrossRef]
    [Google Scholar]
  24. Telenti, A., Marchesi, F., Balz, M., Bally, F., Bottger, E. C. & Bodmer, T. ( 1993;). Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J Clin Microbiol 31, 175–178.
    [Google Scholar]
  25. Telles, M. A. S. & Yates, M. D. ( 1994;). Single and double drug susceptibility testing of Mycobacterium avium complex and mycobacteria other than the tubercle (MOTT) bacilli by a micro-dilution broth minimum inhibitory concentration (MIC) method. Tuber Lung Dis 75, 286–290.[CrossRef]
    [Google Scholar]
  26. Valainis, G. T., Cardona, L. M. & Greer, D. L. ( 1991;). The spectrum of Mycobacterium kansasii disease associated with HIV-I infected patients. J Acquir Immune Defic Syndr 4, 516–520.
    [Google Scholar]
  27. Wallace, R. J., Jr, Nash, D. R., Steele, L. C. & Steingrube, V. A. ( 1986;). Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth. J Clin Microbiol 24, 976–981.
    [Google Scholar]
  28. Witzig, R. S. & Franzblau, S. G. ( 1993;). Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid. Antimicrob Agents Chemother 37, 1997–1999.[CrossRef]
    [Google Scholar]
  29. Witzig, R. S., Fazal, B. A., Mera, R. M., Mushatt, D. M., Dejace, P. M., Greer, D. L. & Hyslop, N. E., Jr ( 1995;). Clinical manifestations and implications of coinfection with Mycobacterium kansasii and human immunodeficiency virus type 1. Clin Infect Dis 21, 77–85.[CrossRef]
    [Google Scholar]
  30. Wolinsky, E. ( 1979;). Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 119, 107–159.
    [Google Scholar]
  31. Wolinsky, E. ( 1981;). When is an infection disease? Rev Infect Dis 3, 1025–1027.[CrossRef]
    [Google Scholar]
  32. Woods, G. L. & Washington, J. A. ( 1987;). Mycobacteria other than Mycobacterium tuberculosis: review of microbiologic and clinical aspects. Rev Infect Dis 9, 275–294.[CrossRef]
    [Google Scholar]
  33. Zhang, Y., Mann, L. B., Wilson, R. W., Brown-Elliott, B. A., Vincent, V., Iinuma, Y. & Wallace, R. J., Jr ( 2004;). Molecular analysis of Mycobacterium kansasii isolates from the United States. J Clin Microbiol 42, 119–125.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.45965-0
Loading
/content/journal/jmm/10.1099/jmm.0.45965-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error